NRX Pharmaceuticals (NRXP) EBITDA (2017 - 2026)

NRX Pharmaceuticals (NRXP) has reported EBITDA for 10 consecutive years, with -$6.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA fell 76.45% year-over-year to -$6.4 million in Q2 2026; TTM through Jun 2026 was -$21.8 million, a 56.57% decrease from a year earlier, with the FY2025 full-year figure at -$16.2 million, up 12.32% from the prior year.
• EBITDA was -$6.4 million for Q2 2026 at NRX Pharmaceuticals, down from -$4.7 million in the prior quarter.
• Over five years, EBITDA peaked at -$2.0 million in Q3 2025 and troughed at -$15.7 million in Q1 2022.
• A 5-year average of -$6.4 million and a median of -$5.9 million in 2023 frame the typical range for EBITDA.
• Across the five-year window, EBITDA jumped 81.33% in 2022 and tumbled 151.72% in 2025, its largest moves.
• Over 5 years, EBITDA stood at -$9.9 million in 2022, then surged by 55.44% to -$4.4 million in 2023, then climbed by 22.33% to -$3.4 million in 2024, then plunged by 151.72% to -$8.6 million in 2025, then gained by 25.64% to -$6.4 million in 2026.
• The last three EBITDA figures came in at -$6.4 million (Q2 2026), -$4.7 million (Q1 2026), and -$8.6 million (Q4 2025), per Business Quant data.